secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001104659-24-058003
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix Q1 net loss $64.8M ($0.49/sh); revenue $14.8M up 10.4% YoY
-----------------------------------------------------------------------------

- Net loss of $64.8M ($0.49/sh) vs $30.3M loss ($0.39/sh) in Q1 2023; includes $28M non-cash loss on debt extinguishment.
- Total net revenue $14.8M, up 10.4% YoY, driven by DEXTENZA product sales.
- Cash and equivalents $482.9M; Feb 2024 private placement raised $325M; cash runway expected into 2028.
- Phase 3 SOL-1 wet AMD trial randomization started April 2024; site activation progressing under FDA SPA.
- Pravin Dugel appointed Exec Chairman, President & CEO; Investor Day set for June 13, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465924058003/0001104659-24-058003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465924058003/tm2413661d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-058003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer